Omeros Announces Reinstatement of Pass-Through Status for Omidria

Omeros announced reinstatement of separate payment by the Centers for Medicare and Medicaid Services (CMS) under the pass-through program for Omidria (phenylephrine and ketorolac intraocular solution) 1%/0.3%. The pass-through status is effective as of October 1, 2018.

Omidria, and a small number of other drugs used during procedures performed on Medicare Part B fee-for-service patients, received a 2-year extension of pass-through reimbursement status as a result of a bipartisan Congressional response to nationwide concerns regarding limited access for Medicare beneficiaries to these drugs due to inadequate reimbursement when payments for the drugs are packaged into their respective procedural fees. The 2-year extension of pass-through for these drugs, including Omidria, was passed into law in March of this year as part of the Consolidated Appropriations Act of 2018, which mandates that the extension remain in effect until October 1, 2020.

Omeros continues to pursue permanent separate payment for Omidria.